ORCHPHARMA vs SANOFI: Stock Comparison

ORCHID PHARMA vs SANOFI INDIAUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SANOFI INDIA is the larger company by market capitalisation. ORCHID PHARMA shows faster revenue growth, while SANOFI INDIA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ORCHPHARMA leads 4; SANOFI leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ORCHPHARMASANOFI

Valuation lens

What price are you paying?

Market CapContext only
₹4,841 Cr
₹7,275 Cr
P/E RatioSANOFI has the lower reading
448.18x
0x
P/B RatioSANOFI has the lower reading
3.07x
0x
EPSSANOFI has the higher reading
₹2.35
₹36.26
Book ValueContext only
₹308.43
₹325.31
Dividend YieldSANOFI has the higher reading
0%
3.96%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SANOFI is the larger company
₹7,275 Cr vs ₹4,841 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 448.18x
P/B Ratio
SANOFI has a lower P/B
0x vs 3.07x
EPS
SANOFI has higher earnings per share
₹36.26 vs ₹2.35
Dividend Yield
SANOFI has a higher dividend yield
3.96% vs 0%
Revenue Growth (TTM YoY)
ORCHPHARMA has faster revenue growth
-1.5% vs -11.9%
EPS Growth (TTM YoY)
ORCHPHARMA has faster EPS growth
0% vs -14.1%
Qtr Sales Growth
ORCHPHARMA has stronger quarterly sales growth
0% vs -7.33%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricORCHPHARMASANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricORCHPHARMASANOFI
Live Price₹954.65₹3,158.2
Day Change2.14%-1.02%
Volume41,6579,898
52-Week High₹1,133₹5,175.5
52-Week Low₹480₹3,054
Distance from 52W High-15.74%-38.98%

Valuation

MetricORCHPHARMASANOFI
Market Cap₹4,841 Cr₹7,275 Cr
P/E Ratio448.18x0x
P/B Ratio3.07x0x
EPS₹2.35₹36.26
Book Value₹308.43₹325.31
Dividend Yield0%3.96%

Growth

MetricORCHPHARMASANOFI
Revenue Growth (TTM YoY)-1.5%-11.9%
EPS Growth (TTM YoY)0%-14.1%
Qtr Sales Growth0%-7.33%
Qtr Profit Growth270.21%-18.62%

Profitability & Leverage

MetricORCHPHARMASANOFI
ROE1.58%41.35%
ROCE2.09%64.11%
Net Margin2.51%19.26%
Operating Margin4.22%23.62%
Debt to Equity0.28x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricORCHPHARMASANOFI
Promoter Holding69.84%0%
FII Holding0.81% 0.06 pp5.69% 0.05 pp
DII Holding20.75% 0.5 pp19.87% 1.26 pp
Public Holding8.61% 0.44 pp14.04% 1.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ORCHID PHARMA and SANOFI INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.